ZA200704532B - Process for the preparation of 4-(6-chloro-2, 3-methylene-dioxyanilino)-7-[2-(4-methyl piperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof - Google Patents

Process for the preparation of 4-(6-chloro-2, 3-methylene-dioxyanilino)-7-[2-(4-methyl piperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof Download PDF

Info

Publication number
ZA200704532B
ZA200704532B ZA200704532A ZA200704532A ZA200704532B ZA 200704532 B ZA200704532 B ZA 200704532B ZA 200704532 A ZA200704532 A ZA 200704532A ZA 200704532 A ZA200704532 A ZA 200704532A ZA 200704532 B ZA200704532 B ZA 200704532B
Authority
ZA
South Africa
Prior art keywords
formula
compound
azd0530
salt
quinazoline
Prior art date
Application number
ZA200704532A
Other languages
English (en)
Inventor
Ford James Gair
O'kearney-Mcmullan Anne
Pointon Simon Mark
Purdie Mark
Mccabe James Francis
O'keefe Philip
Powell Lyn
Withnall Jane
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200704532B publication Critical patent/ZA200704532B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200704532A 2004-12-17 2007-05-31 Process for the preparation of 4-(6-chloro-2, 3-methylene-dioxyanilino)-7-[2-(4-methyl piperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof ZA200704532B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process

Publications (1)

Publication Number Publication Date
ZA200704532B true ZA200704532B (en) 2008-07-30

Family

ID=34090249

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200704532A ZA200704532B (en) 2004-12-17 2007-05-31 Process for the preparation of 4-(6-chloro-2, 3-methylene-dioxyanilino)-7-[2-(4-methyl piperazin-1-yl) ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof

Country Status (16)

Country Link
US (1) US8304417B2 (ko)
EP (1) EP1871769B1 (ko)
JP (2) JP5161584B2 (ko)
KR (6) KR20080094847A (ko)
CN (1) CN101115744B (ko)
AU (2) AU2005315458B2 (ko)
BR (1) BRPI0519085A2 (ko)
CA (2) CA2590735C (ko)
ES (1) ES2622480T3 (ko)
GB (1) GB0427697D0 (ko)
IL (1) IL183525A0 (ko)
MX (1) MX2007007210A (ko)
NO (1) NO20072755L (ko)
NZ (1) NZ555468A (ko)
WO (1) WO2006064217A2 (ko)
ZA (1) ZA200704532B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
WO2016130897A1 (en) 2015-02-13 2016-08-18 Yu Paul B Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
EP3930715B1 (en) 2019-02-27 2024-05-08 Astrazeneca AB Saracatinib for use in the treatment of idiopathic pulmonary fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20080027400A (ko) 2000-08-21 2008-03-26 아스트라제네카 아베 퀴나졸린 유도체
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
AU2003278383B2 (en) * 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
GB0427697D0 (en) 2005-01-19
KR20080094847A (ko) 2008-10-24
KR20110114727A (ko) 2011-10-19
IL183525A0 (en) 2007-09-20
ES2622480T3 (es) 2017-07-06
WO2006064217A2 (en) 2006-06-22
CA2590735C (en) 2009-11-10
AU2005315458B2 (en) 2009-03-12
CA2675642A1 (en) 2006-06-22
US20090099196A1 (en) 2009-04-16
AU2009200622A1 (en) 2009-03-12
AU2005315458A1 (en) 2006-06-22
EP1871769A2 (en) 2008-01-02
KR20080094849A (ko) 2008-10-24
KR20080094848A (ko) 2008-10-24
WO2006064217A3 (en) 2006-12-21
NZ555468A (en) 2010-12-24
CA2590735A1 (en) 2006-06-22
MX2007007210A (es) 2007-11-07
JP2008524183A (ja) 2008-07-10
NO20072755L (no) 2007-07-02
WO2006064217A8 (en) 2007-07-05
EP1871769B1 (en) 2017-02-22
JP2009143920A (ja) 2009-07-02
BRPI0519085A2 (pt) 2008-12-23
JP5161584B2 (ja) 2013-03-13
US8304417B2 (en) 2012-11-06
KR20070090004A (ko) 2007-09-04
CN101115744B (zh) 2012-02-01
KR20080094846A (ko) 2008-10-24
CN101115744A (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
EP1480650B1 (en) Novel crystalline forms of the anti-cancer compound zd1839
EP1971601B1 (en) N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EP3686194B1 (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
US8304417B2 (en) Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
CA2845630C (en) Amino quinazolines as kinase inhibitors
CA3088381A1 (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
KR20140027985A (ko) 암 치료용 ｐｉ 3-키나제 억제제로서의 크로메논 화합물
CN111566101B (zh) Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
ZA200406729B (en) Novel crystalline forms of the anti-cancer compound ZD 1839.